NEW YORK (Reuters Health) April 16 Pentoxifylline therapy provides only limited efficacy against recurrent aphthous stomatitis and should not be considered a first-line agent, new research indicates.
Ernst et al. [36] conducted a randomized, double-blind study in 40 patients to assess whether pentoxifylline 1200 mg/day in combination with exercise increased ACD and ICD compared with placebo plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results